References
- Mayer RJ, Davis RB, Schiffer CA, et al. Comparative evaluation of intensive post-remission therapy with different dose schedules of ARA-C in adults with acute myeloid leukemia (AML): Preliminary results of CALGB phase Ill study. Hae-matologica 1991; 76: 97, Suppl 4
- Adriaansen HJ, Hooijkaas H, Kappers-Klunne MC, et al. Detection of minimal residual disease in ANLL patients by use of double immunologic marker analysis for TdT and a myeloid marker. J Cell Biochem 1991; 15: 14, Suppl G
- Meloni G, Tosti S, Vignetti M, et al. IL2 treatment for limited resistant disease in relapsed AML patients. Exp Hematol 1991; 19: 535
- Faber LM, Willemze R, Falkenburg JHF. Leukemia-specific cytotoxic T lymphocyte (CTL) clones can be generated in vitro by stimulation of HLA-genotypically identical donor cells with recipient leukemic cells. Exp Hematol 1991; 19: 586
- Wiernik PH, Dutcher JP, Todd M, et al. Polyethylene glycolated (PEG) interleukin-2 (IL-2) as maintenance therapy for acute myelogenous leukemia (AML) in second remission (CR). Blood 1991; 78: 42a, Suppl 1
- Santini V, van Putten W, Delwei R, et al. Spontaneous in vitro prolife:ration of primary acute myeloid leukemia: Clinical relevance. Blood 1991; 78: 45a, Suppl 1
- Slapak Desforges CA., Jr, Fogaren T, et al. The treatment of acute myeloid leukemia (AML) in the elderly with low-dose lcytarabine, hydroxyurea and calcitriol. Blood 1991; 78: 50a, Suppl 1
- Caron PC, Co MS, Bull MK, et al. Humanized M195 (anti-CD33) monoclonal antibodies: Potential for therapy of myelogenous leukemia. Blood 1991; 78: 268a, Suppl 1
- Warrell RP, Muindi J, Frankel SR, et al. Continuous treatment with all trans-retinoic acid progressively decreases plasma drug concentrations: Implications for relapse and resistance in acute promyelocytic leukemia. Blood 1991; 78: 268a, Suppl 1
- Raza A, Yousuf N, Abbas A, et al. Cell cycle characteristics predict for remission duration (rem dur) in 122 standard risk newly diagnosed patients with acute myeloid leukemia (AML). Blood 1991; 78: 380a., Suppl 1
- Van Etten RA. Distinct effect of expression of the ALL-specific form of BCRIABL, P190bcr/abl in murine bone marrow. Blood 1991; 78: 78a, Suppl 1
- Uckun FM, Manivel JC, Gunther R, et al. Human B-lineage acute lymphoblastic leukemia (ALL) in severe combined immunodeficiency (SCID) mice: Ability of primary leukemic B-cell precursors (BCP) from newly diagnosed B-lineage ALL patients to cause leukemia in immunodeficient CB. 17 SCID mice may be associated with poor clinical outcome. Blood 1991; 78: 382a, Suppl 1
- Higano CS, Raskind W, Singer JW. Alpha interferon (ifn) treatment of chronic myelogenous leukemia (CML) in relapse after allogeneic marrow transplantation (BMT): A prospective trial. Blood 1991; 78: 290a, Suppl 1
- Yuan TY, Chen HC, Herst CV, et al. Antisense oligonucleotides to BRC-ABL mRNA inhibit synthesis of p210bcr/abl protein and reduce viability in cultures of Philadelphia chromosome positive cells. Blood 1991; 78: 329a, Suppl 1
- Burke PJ. Remission of aggressive phase chronic myelocytic leukemia (CML) with timed sequential therapy (TST) and interferon (I) given in aplasia. Haematologica 1991; 76: 38, Suppl 4
- Escudier SM, Pereira-Leahy JM, Goodacre AM, et al. Fluorescence in situ hybridization (FISH) and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia (CLL). Blood 1991; 78: 329a, Suppl 1
- del Giglio A, Khetan R, O'Brien S, et al. Proliferating cell nuclear antigen levels are high in advanced stage chronic lymphocytic leukemia and correlate with clinical doubling time of this disease. Blood 1991; 78: 311a, Suppl l
- Juliusson G, Liliemark J. 2-Chloro-2'-deoxyaden-osine (CdA) induces complete remission in B-cell chronic lymphocytic leukemia cells resistant to fludarabine (FAMP). Blood 1991; 78: 269a, Suppl 1
- Robertson L, Chubb S, Hittelman WN, et al. Programmed death (apoptosis) in chronic lymphocytic leukemia cells after fludarabine and chlorodeoxy-adenosine. Blood 1991; 78: 173a, Suppl 1
- van Kooten C, Rensink HJAM, Aarden LA, et al. TNFa-induced proliferation of B-chronic lymphocytic leukemia cells is inhibited by IL4. Blood 1991; 78: 112a, Suppl 1
- Kemena A, Keating MJ, Plunkett W. Plasma and cellular bioavailability of oral fludarabine. Blood 1991; 78: 52a, Suppl 1
- Villalona-Calero M, Stewart C, Barcos M, et al. Phenotypic characteristics of “prolymphocytoid” transformed (CLL/PLL) chronic lymphocytic leukemia (CLL) cells. Proc ASCO 1991; 10: 230